Encouraging response rate shown; CR in 67% (6/9) of patients who completed the Induction Treatment Phase Padeliporfin VTP generally well-tolerated, consistent with prior results and reinforcing differentiated organ-sparing profile Preliminary data presented in a podium session at AUA; additional interim results to be presented at ASCO TEL AVIV, Israel, May 06, 2024 (GLOBE NEWSWIRE) — … Continued

Preliminary results from Phase 3 ENLIGHTED study in low grade upper tract urothelial cancer (UTUC) to be presented at AUA and ASCO Trial design for Phase 1 study of Padeliporfin VTP in pancreatic ductal adenocarcinoma (PDAC) to be presented at ASCO TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology … Continued

TEL AVIV, Israel, Dec. 18, 2023 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy to treat a range of solid tumors, today announced the appointment of Eyal Morag, M.D., as Chief Medical Officer (CMO). Dr. Morag brings extensive experience as a practicing clinical radiologist, specializing in … Continued

Phase 1 clinical trial expected to initiate in 1H 2024 IND clearance in third indication reflects broad platform potential for Padeliporfin VTP across a range of solid tumors   TEL AVIV, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy to treat … Continued

ImPact Biotech to collaborate with Maastricht University researchers to progress a treatment to arrest the progressive condition Pathologic Myopia, a leading cause of irreversible sight impairment and blindness among adults   TEL AVIV, August 13, 2023 — ImPact Biotech, a leader in photodynamic therapy, recently announced an agreement with Maastricht University to collaborate in research focused … Continued